Bank of America Merrill Lynch Maintains Neutral on Edwards Lifesciences

Bank of America Merrill Lynch is out with its report today on Edwards Lifesciences EW, maintaining Neutral. In a note to clients, Bank of America Merrill Lynch writes, "Over the next five-plus years, there is no other new product opportunity in medtech of a similar potential size as the transcatheter aortic valve implantation market, and EW is the only stand-alone player. EW has this opportunity at a time when large-cap medtech is severely growth challenged and threatened by margin uncertainty given health care reform, but flush with cash. We believe TAVI will stand alongside coronary stents as a core technology in the catheterization lab of the future." Shares of EW closed Thursday at $82.55, down 5.69% from Wednesday's close.